# US 10,307,388 B2 · Compositions and methods for diagnosis and treatment of inflammation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,388 B2 - Document ID: US10307388B2 - Status: Granted - Kind: B2 - Application number: 15/393,799 - Filed: 2016-12-29 - Published: 2018-07-05 - Granted: 2019-06-04 - Earliest claimed: 2016-12-29 - Assignees: The United States of America as represented by the Secretary of the Navy - Applicants: The United States of America as represented by the Secretary of the Navy - Inventors: Stephanie Kay Venn-Watson - Web page: https://patentgrep.com/patent/US10307388B2 ## CPC - A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/06: Antihyperlipidemics - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 5/50: for increasing or potentiating the activity of insulin - A61P 7/06: Antianaemics - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/12: Antihypertensives - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 35/00: Antineoplastic agents - A61P 37/02: Immunomodulators - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions. ## Claims ### Claim 1 A method of treatment of inflammation, comprising: administering to a patient in need thereof a composition comprising an effective amount of at least one odd-chain saturated fatty acid, or pharmaceutically acceptable salts thereof, wherein the at least one odd-chain saturated fatty acid is selected from the group consisting of C15:0, C17:0, and combinations thereof. ### Claim 2 (depends on 1) The method of claim 1, wherein the at least one odd-chain saturated fatty acid or pharmaceutically acceptable salts thereof is provided as a pharmaceutical composition in a unit dosage form comprising the at least one odd-chain saturated fatty acid or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. ### Claim 3 (depends on 1, 2) The method of any one of claims 1 through 2, wherein the unit dosage form comprises from 0.01 mg to 10000 mg of the at least one odd-chain saturated fatty acid or pharmaceutically acceptable salts thereof. ### Claim 4 (depends on 1, 2, 3) The method of any one of claims 1 through 3, wherein the at least one odd chain saturated fatty acids is heptadecanoic acid or pentadecanoic acid. ### Claim 5 (depends on 1, 2, 3, 4) The method of any one of claims 1 through 4, wherein the pharmaceutical composition is substantially free from even chain saturated fatty acids. ### Claim 6 (depends on 1, 2, 3, 4, 5) The method of any one of claims 1 through 5, wherein the pharmaceutical composition comprises a plurality of different odd-chain saturated fatty acids. ### Claim 7 (depends on 1, 2, 3, 4, 5, 6) The method of any one of claims 1 through 5 or 6, wherein from 2.5 mg to 11 mg of the at least one odd-chain saturated fatty acid or pharmaceutically acceptable salts thereof is administered to the patient, per 1 kg of body weight, per day. ### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7) The method of any one of claims 1 through 5 or 6-7, wherein the at least one odd-chain saturated fatty acid or pharmaceutically acceptable salts thereof is administered to the patient once per day. ### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8) The method of any one of claims 1 through 5 or 6-8, wherein a serum concentration or a red blood cell membrane concentration of the at least one odd-chain saturated fatty acid is increased by at least about 0.001×10−4 M above a pretreatment value. ### Claim 10 (depends on 1) The method of treatment of claim 1, wherein the composition further comprises an effective amount of at least one even-chain saturated fatty acid, wherein the at least one even-chain saturated fatty acid is selected from the group consisting of C16:0, C18:0, and combinations thereof. ### Claim 11 (depends on 1) The method of treatment of claim 1, wherein the composition further comprises an effective amount of at least one very long even chain saturated fatty acid, wherein the at least one very long even chain saturated fatty acid is selected from the group consisting of C20:0, C:22:0, and C24:0, and combinations thereof. ### Claim 12 (depends on 10) The method of treatment of claim 10, wherein the composition further comprises an effective amount of at least one very long even chain saturated fatty acid, wherein the at least one very long even chain saturated fatty acid is selected from the group consisting of C20:0, C:22:0, and C24:0, and combinations thereof.